Stockreport

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 [Yahoo! Finance]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF Received US FDA Fast Track Designation for MRT-2359 for previously treated, metastatic small cell lung cancer with L- or N-MYC expression MRT-6160, a VAV1-directed MG [Read more]